French pharmaceutical company Sanofi has started human trials for a second coronavirus vaccine, it announced on Friday.
Sanofi and US company Translate Bio announced “the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes Covid-19,” adding that “the companies expect interim results from this trial in the third quarter of 2021.”
“Initiating the Phase 1/2 trial represents an important step forward in our goal of bringing another effective vaccine to the ongoing fight against the COVID-19 pandemic,” said Sanofi Executive Vice-President and Global Head Thomas Triomphe.
- Vaccinations: Appointments being cancelled after Danish concerns over AstraZeneca
- Johnson & Johnson vaccine given EU authorisation
Sanofi will test 415 people in a first instance.
Another Sanofi vaccine is still in a test phase after disappointing results in autumn 2020.
The Brussels Times